Proton beam boost: could fewer sessions mean better prostate cancer control?

NCT ID NCT04486755

Ongoing Disease control Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether giving higher doses of radiation to the prostate in fewer sessions (while also treating pelvic lymph nodes) is safe for men with intermediate- to high-risk prostate cancer. The study enrolls 18 adults and uses proton beam therapy delivered four days per week. The main goal is to find a schedule that limits severe short-term side effects like bowel, bladder, or nerve problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hypofractionated proton beam radiation therapy
What this could lead to: If successful, this could lead to a shorter, more convenient radiation schedule that delivers a stronger dose to the prostate while keeping side effects manageable.
What could go wrong: This is a very early phase 1 trial with only 18 participants, so results may not apply to all patients. The higher radiation dose could increase the risk of bowel, bladder, or nerve side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE ADENOCARCINOMA PROSTATE CANCER

Contacts and locations

Locations

Maryland Proton Treatment Center

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.